Preliminary Data from Two Clinical Trials with ADC Candidates were ...
Jun 5, 2025 · The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio (HKEX: 9606.HK) presented the preliminary data of two clinical trials, HER3 ADC …
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast ...
Jun 2, 2025 · “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said , M.D., Ph.D., Chief Medical Officer, Solid Tumors at …
Adcentrx Therapeutics to Present First Clinical Data for ADRX-0706 ...
Apr 23, 2025 · Adcentrx will deliver a poster presentation on ADRX-0706, a clinical-stage Nectin-4 ADC. The presentation will include interim clinical data from the Phase 1a portion of the ongoing trial …
Results from the Phase 1 Clinical Trial of Henlius PD-L1 ADC HLX43 ...
Jun 3, 2025 · The results presented at the 2025 ASCO Annual Meeting were from the phase 1 clinical study, which evaluated the safety, tolerability, and pharmacokinetic characteristics of HLX43 (Anti …
AbbVie’s ASCO 2025 ADC breakthroughs: Transforming oncology with …
Jun 9, 2025 · AbbVie unveils new ADC data at ASCO 2025 – exploring groundbreaking therapies in lung cancer, NENs & BPDCN. Dr. Daejin Abidoye discusses the latest findings & patient advocacy efforts. …
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and ...
May 27, 2025 · AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio
ASCO 2025 | Dr. Jie Wang Presents China’s First PD-L1–Targeted ADC ...
Jun 25, 2025 · From a mechanistic perspective, what advantages does HLX43 bring to cancer therapy? Dr. Jie Wang: HLX43 is the world’s first PD-L1–targeted ADC to advance into phase II clinical trials. …
2025 ASCO: Domestic ADCs, Bispecifics, Trispecifics, Small Molecules
May 28, 2025 · Explore the major highlights from ASCO 2025, featuring cutting-edge Chinese innovations in ADCs, bispecific and trispecific antibodies, and small molecule drugs with promising …
ASCO25: AbbVie flexes ADC Phase I data as NSCLC market …
Jun 3, 2025 · AbbVie’s antibody drug conjugate (ADC) Temab-A (telisotuzumab adizutecan) has demonstrated promising results in a Phase I trial in patients with lung cancer, as the ADC modality …
ASCO 2025 Recap: Rise of the Bispecifics, Dueling Degraders, ADCs of ...
Jun 15, 2025 · At ASCO, Genmab reported new data from the dose-expansion cohort of a multi-part Phase 1/2 study in endometrial cancer.